Joshua Grass

Joshua Grass is a biopharmaceutical executive and venture capitalist, serving as CEO of Escient Pharmaceuticals and a Venture Partner at 5AM Ventures. He leverages his background in biology, from California Polytechnic State University, and his MBA from the University of Rochester to lead and invest in life science companies.

His career focus on pharmaceuticals, with previous roles at Elan Pharmaceuticals and Neurocrine Biosciences, suggests a deep-seated passion for advancing medical science. He also maintains a connection to his alma mater, Cal Poly, listing it as a key interest, indicating a potential loyalty to the institution and its programs.

Under his leadership, Escient Pharmaceuticals nominated its second clinical candidate, a novel mrgprX2 inverse agonist.